SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift reports net loss of Rs 62.90 crore in Q1

29 Aug 2012 Evaluate

Ind-Swift has reported results for first quarter ended June 30, 2012.

On standalone basis, the company has reported a net loss of Rs 62.90 crore for the quarter ended June 30, 2012 against net profit of Rs 15.34 crore for the corresponding period last fiscal.  However, total income increased by 63.31% at Rs 392.66 crore during the quarter under review from Rs 240.43 crore in the year-ago period.

Ind-Swift is a fully integrated pharma group. The API required for the product was supplied from the USFDA and MHRA approved plant of Ind-Swif Laboratories and the formulations was manufactured and supplied from the 100% export facility of Ind-Swift located near Derabassi Punjab.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×